Infusion treatments and deep brain stimulation in Parkinson's Disease: The role of nursing

Lees, 2009, Parkinson's disease, Lancet, 13, 2055, 10.1016/S0140-6736(09)60492-X de Lau, 2006, Epidemiology of Parkinson's disease, Lancet Neurol, 5, 525, 10.1016/S1474-4422(06)70471-9 Chaudhuri, 2009, Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment, Lancet Neurol, 8, 464, 10.1016/S1474-4422(09)70068-7 Aquino, 2015, Clinical spectrum of levodopa-induced complications, Mov Disord, 30, 80, 10.1002/mds.26125 Jankovic, 2005, Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations, Mov Disord, 20, S11, 10.1002/mds.20458 Valldeoriola, 2013, Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study, J Med Econ, 16, 191 Benabid, 1987, Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease, Appl Neurophysiol, 50, 344 Krack, 1998, Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson’s disease, Brain, 121, 451, 10.1093/brain/121.3.451 Chen, 2012, Deep brain stimulation, Interv Neurol, 1, 200, 10.1159/000353121 Follett, 2010, Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease, N Engl J Med, 362, 2077, 10.1056/NEJMoa0907083 Okun, 2012, Deep-brain stimulation for Parkinson's disease, N Engl J Med, 367, 1529, 10.1056/NEJMct1208070 Volkmann, 2013, Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review, J Neurol, 260, 2701 Rizzone, 2014, Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage of the disease?, Parkinsonism Relat Disord, 20, 376, 10.1016/j.parkreldis.2014.01.012 Benabid, 2009, Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease, Lancet Neurol, 8, 67, 10.1016/S1474-4422(08)70291-6 Picillo, 2016, Programming deep brain stimulation for Parkinson's disease: the Toronto Western hospital algorithms, Brain Stimul, 9, 425, 10.1016/j.brs.2016.02.004 Defer, 1999, Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD), Mov Disord, 14, 572, 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C Lang, 2006, Deep brain stimulation: preoperative issues, Mov Disord, 21, 171, 10.1002/mds.20955 Deuschl, 2013, Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study, Park Relat Disord, 19, 56, 10.1016/j.parkreldis.2012.07.004 Alegret, 2001, Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease, Arch Neurol, 58, 1223, 10.1001/archneur.58.8.1223 Dujardin, 2001, Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson’s disease, J Neurol, 248, 603 Berney, 2002, Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients, Neurology, 59, 1427, 10.1212/01.WNL.0000032756.14298.18 Fukaya, 2015, Deep brain stimulation for Parkinson's disease: recent trends and future direction, Neurol Med Chir (Tokyo), 55, 422, 10.2176/nmc.ra.2014-0446 Chan, 2009, Complications of deep brain stimulation: a collective review, Asian J Surg, 32, 258, 10.1016/S1015-9584(09)60404-8 Smeding, 2006, Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study, Neurology, 66, 1830, 10.1212/01.wnl.0000234881.77830.66 Russmann, 2004, Subthalamic nucleus deep brain stimulation in Parkinson disease patients over 70 year, Neurology, 63, 1952, 10.1212/01.WNL.0000144198.26309.D8 Sanghera, 2004, High-frequency stimulation of the subthalamic nucleus for the treatment of Parkinson's disease–a team perspective, J Neurosci Nurs, 36, 301, 10.1097/01376517-200412000-00003 Byrd, 2000, Deep brain stimulation for advanced Parkinson's disease, AORN J, 72, 387, 10.1016/S0001-2092(06)61274-X Hunka, 2005, Nursing time to program and assess deep brain stimulators in movement disorder patients, J Neurosci Nurs, 37, 204, 10.1097/01376517-200508000-00006 Schwab, 1951, Apomorphine in Parkinson’s disease, Trans Am Neurol Assoc, 56, 251 Muguet, 1995, Apomorphine in patients with Parkinson’s disease, Biomed Pharmacother, 49, 197, 10.1016/0753-3322(96)82620-5 Boyle, 2015, Role of apomorphine in the treatment of Parkinson's disease, CNS Drugs, 29, 83, 10.1007/s40263-014-0221-z Koller, 2004, Other formulations and future considerations for apomorphine for subcutaneous injection therapy, Neurology, 62, S22, 10.1212/WNL.62.6_suppl_4.S22 De Gaspari, 2006, Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus, J Neurol Neurosurg Psychiatry, 77, 450, 10.1136/jnnp.2005.078659 Alegret, 2004, Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease, Mov Disord, 19, 1463, 10.1002/mds.20237 Drapier, 2012, Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications, Park Relat Disord, 18, 40, 10.1016/j.parkreldis.2011.08.010 Trenkwalder, 2015, Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease–clinical practice recommendations, Park Relat Disord, 21, 1023, 10.1016/j.parkreldis.2015.06.012 Antonini, 2009, Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management, Expert Rev Neurother, 9, 859, 10.1586/ern.09.48 Antonini, 2009, Apomorphine and levodopa infusion therapies for advanced Parkinson's disease, Mov Disord, 2, 4, 10.14802/jmd.09002 Kulisevsky, 2013, Advanced Parkinson's disease: clinical characteristics and treatment. Part II, Neurologia, 28, 558, 10.1016/j.nrl.2013.05.002 McGee, 2002, Apomorphine treatment: a nurse’s perspective, Adv Clin Neurosci Rehabil, 2, 23 Poewe, 2015, Novel formulations and modes of delivery of levodopa, Mov Disord, 30, 114, 10.1002/mds.26078 Nyholm, 2005, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease, Neurology, 64, 216, 10.1212/01.WNL.0000149637.70961.4C Nyholm, 2006, Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease, Expert Rev Neurother, 6, 1403, 10.1586/14737175.6.10.1403 Antonini, 2007, Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome, Mov Disord, 22, 1145, 10.1002/mds.21500 Antonini, 2008, Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease, Neurodegener Dis, 5, 244, 10.1159/000113714 Merola, 2011, Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson’s disease, Mov Disord, 26, 664, 10.1002/mds.23524 Zibetti, 2014, Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, Eur J Neurol, 21, 312, 10.1111/ene.12309 Pedersen, 2012, Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic, Open Neurol J, 6, 37, 10.2174/1874205X01206010037 Abbruzzese, 2012, Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection, Funct Neurol, 27, 147 Devos, 2009, Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease, Mov Disord, 24, 993, 10.1002/mds.22450 Toth, 2010, Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease, Ann Neurol, 68, 28, 10.1002/ana.22021 Klostermann, 2012, Malnutritional neuropathy under intestinal levodopa infusion, J Neural Transm, 119, 369, 10.1007/s00702-011-0689-3